Clinical case of transmitted resistance to HIV Integrase Inhibitors González-Domenech CM 1 , Viciana I 1,2 , Jarilla F 3 , Palacios R 1,2 , Roldán J 3 , Santos J 1,2 1 Biomedical Research Institute of Malaga (IBIMA), Málaga, Spain; 2 Infectious Diseases and Clinical Microbiology Unit, Virgen de la Victoria Hospital, Málaga, Spain; 3 Service of Internal Medicine, Antequera Local Hospital, Málaga, Spain 2 nd Global HIV Clinical Forum on Integrase Inhibitors. 22 nd July, 2017. Paris (France)
15
Embed
Clinical case of transmitted resistance to HIV Integrase ...regist2.virology-education.com/2017/2GlobalHCF/08_Domenech.pdf · Clinical case of transmitted resistance to HIV Integrase
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Clinical case of transmitted resistance to HIV Integrase
1Biomedical Research Institute of Malaga (IBIMA), Málaga, Spain; 2Infectious Diseases and Clinical
Microbiology Unit, Virgen de la Victoria Hospital, Málaga, Spain; 3Service of Internal Medicine,
Antequera Local Hospital, Málaga, Spain
2nd Global HIV Clinical Forum on Integrase Inhibitors. 22nd July, 2017. Paris (France)
Clinical case of transmitted resistance to HIV Integrase Inhibitors2nd Global HIV Clinical Forum
Background
Recommendations about resistance of HIV-1 to antiretroviral drugs
Assessment of baseline integrase resistance mutations is only recommended when there is a highsuspicion of transmission of resistance to integrase strand transfer inhibitors (INSTI).Multiple resistance in PR and/or RT or index patient treated with INSTI
Resistance should be studied by genotyping in all patients in whom virological failure has beenconfirmed. The study should include integrase resistance mutations if the patient's regimenincludes an INSTI
The Spanish Aids Research Network (RIS) study during period
2007-2012 Overall prevalence for protease and reverse